Home / Market News / $RCKT

$RCKT news and market catalysts

The 7 most recent market catalysts affecting $RCKT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

7 catalysts 1 high impact 3 bullish 2 bearish Biotechnology
Nov 16, 2026 Corporate Catalyst Neutral Impact 55
Analysts Update Ratings and Price Targets for Rocket Pharmaceuticals
On November 14, 2026, several Wall Street analysts provided updated coverage for Rocket Pharmaceuticals. While Needham and CCORF maintained 'buy' ratings, Wedbush lowered its price…
Nov 12, 2026 Corporate Catalyst Neutral Impact 75
Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results
Rocket Pharmaceuticals (RCKT) filed an 8-K to report its third-quarter 2026 financial results and provide a business update. The most significant disclosure is the FDA alignment on…
Oct 8, 2026 Corporate Catalyst Bullish Impact 55
Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4
Goldman Sachs analyst Richard Law upgraded Rocket Pharmaceuticals (RCKT) from a 'Sell' to a 'Neutral' rating and raised the price target from $3 to $4. This change in analyst senti…
Oct 6, 2026 Corporate Catalyst Bullish Impact 75
Rocket Pharmaceuticals Announces Up To $150M Credit Facility With Hercules Capital, $35M Received At Closing; Expects Cash Runway Into Q3 2028
This announcement is a significant positive for Rocket Pharmaceuticals, as it addresses a common concern for biotech companies: cash burn and funding. The $150M credit facility, wi…
Aug 11, 2026 Corporate Catalyst Bearish Impact 55
Wedbush Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $15
Wedbush analyst Yun Zhong maintained an 'Outperform' rating on Rocket Pharmaceuticals (RCKT) but lowered the price target from $16 to $15. This action signals that while the analys…
Aug 10, 2026 Corporate Catalyst Bearish Impact 95
Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 Estimate
Rocket Pharmaceuticals announced its Q2 adjusted EPS, reporting a loss of $(0.37) per share, which dramatically missed the analyst consensus estimate of a $0.24 gain. This 254.17% …
Aug 3, 2026 Corporate Catalyst Bullish Impact 75
Rocket Pharma Announces Clinical Safety Update Regarding Initial Three Patients Treated Under Modified Protocol For Global, Pivotal Phase 2 Trial Of RP-A501 In Danon Disease
Rocket Pharma reported that the initial three patients treated with RP-A501 for Danon disease under a modified protocol showed positive safety, with no thrombotic microangiopathy (…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.